Abstract
Editorial: Ubiquitin-Modifying Enzymes as Drug Targets and Biomarkers in Cancer
Highlights
Specialty section: This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
The RING-finger family has the most members and contain ligases such as the anaphase-promoting complex (APC) and the SCF complex (Skp1-Cullin-F-box protein complex), as well as many TRIM proteins. These proteins are key regulators of cell fate in both non-malignant cells and cancer cells by adding ubiquitin to proteins and are increasingly targets for pharmaceutical modulation. They are opposed to another class of enzymes referred to as deubiquitinating enzymes from protein families such as ubiquitinspecific proteases (USPs), Ubiquitin Cterminal hydrolases (UCHs), OTU, JAMM, MCPIP, which have become drug targets
Review and research papers were accepted focusing on cancer related ubiquitin-modifying enzymes as; biomarkers, therapeutic targets, as an interacting partner of a clinically significant protein in cancer/cancer models and cancer cell phenotypes
Summary
Specialty section: This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology. Editorial: Ubiquitin-Modifying Enzymes as Drug Targets and Biomarkers in Cancer Editorial on the Research Topic Ubiquitin-Modifying Enzymes as Drug Targets and Biomarkers in Cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
